Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
- PMID: 26001389
- DOI: 10.1136/gutjnl-2014-309026
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
Abstract
Objective: Microsatellite instability (MSI) is detected in approximately 15% of all colorectal cancers (CRC) and virtually in all cases with Lynch syndrome. The MSI phenotype is caused by dysfunctional mismatch repair (MMR) and leads to accumulation of DNA replication errors. Sporadic MSI CRC often harbours BRAF(V600E); however, no consistent data exist regarding targeted treatment approaches in BRAF(wt) MSI CRC.
Design: Mutations and quantitative MSI were analysed by deep sequencing in 196 formalin fixed paraffin embedded (FFPE) specimens comprising Lynch and Lynch-like CRCs from the German Hereditary Nonpolyposis Colorectal Cancer registry. Functional relevance of recurrent ERBB2/HER2 mutations was investigated in CRC cell lines using reversible and irreversible HER-targeting inhibitors, EGFR-directed antibody cetuximab, HER2-directed antibody trastuzumab and siRNA-mediated ERBB2/HER2 knockdown.
Results: Quantification of nucleotide loss in non-coding mononucleotide repeats distinguished microsatellite status with very high accuracy (area under curve=0.9998) and demonstrated progressive losses with deeper invasion of MMR-deficient colorectal neoplasms (p=0.008). Characterisation of BRAF(wt) MSI CRC revealed hot-spot mutations in well-known oncogenic drivers, including KRAS (38.7%), PIK3CA (36.5%), and ERBB2 (15.0%). L755S and V842I substitutions in ERBB2 were highly recurrent. Functional analyses in ERBB2-mutated MSI CRC cell lines revealed a differential response to HER-targeting compounds and superiority of irreversible pan-HER inhibitors.
Conclusions: We developed a high-throughput deep sequencing approach for concomitant MSI and mutational analyses in FFPE specimens. We provided novel insights into clinically relevant alterations in MSI CRC and a rationale for targeting ERBB2/HER2 mutations in Lynch and Lynch-like CRC.
Keywords: CANCER GENETICS; CANCER SYNDROMES; COLORECTAL NEOPLASM; GENE TARGETING; MOLECULAR ONCOLOGY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Similar articles
-
Microsatellite instability: an update.Arch Toxicol. 2015 Jun;89(6):899-921. doi: 10.1007/s00204-015-1474-0. Epub 2015 Feb 22. Arch Toxicol. 2015. PMID: 25701956 Review.
-
BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.Tumori. 2014 May-Jun;100(3):315-20. doi: 10.1700/1578.17214. Tumori. 2014. PMID: 25076244
-
Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.World J Gastroenterol. 2015 Aug 21;21(31):9253-61. doi: 10.3748/wjg.v21.i31.9253. World J Gastroenterol. 2015. PMID: 26309352 Free PMC article. Review.
-
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19. Eur J Cancer. 2017. PMID: 29055842
-
Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.Cancer. 2015 Jun 1;121(11):1762-71. doi: 10.1002/cncr.29288. Epub 2015 Feb 24. Cancer. 2015. PMID: 25712738
Cited by
-
Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001016. doi: 10.1101/mcs.a001016. Cold Spring Harb Mol Case Stud. 2016. PMID: 27626067 Free PMC article.
-
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.Nat Commun. 2021 May 19;12(1):2940. doi: 10.1038/s41467-021-23271-0. Nat Commun. 2021. PMID: 34011995 Free PMC article.
-
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.BMC Cancer. 2019 Sep 5;19(1):880. doi: 10.1186/s12885-019-6051-0. BMC Cancer. 2019. PMID: 31488078 Free PMC article.
-
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.J Pathol. 2016 Mar;238(4):562-70. doi: 10.1002/path.4679. Epub 2016 Jan 29. J Pathol. 2016. PMID: 26690310 Free PMC article.
-
Recapitulating the adenoma-carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids.Nat Cancer. 2024 Dec;5(12):1852-1867. doi: 10.1038/s43018-024-00841-x. Epub 2024 Nov 1. Nat Cancer. 2024. PMID: 39487295 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous